Atlas Venture closed its fourteenth fund, securing $450 million to invest in and cultivate new biotech startups focused on developing innovative medicines.
Maze Therapeutics has completed a $115 million Series D financing to support the development of precision medicines for renal, cardiovascular, and metabolic diseases.
Maze Therapeutics announced positive Phase 1 results for MZE829, an oral APOL1 inhibitor, in healthy volunteers, showing it was well-tolerated with dose-proportional pharmacokinetics.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.